Our Research
CREDENCE Trial
Sponsor: Janssen
​
Protocol: 28431754DNE3001 (Phase 3) (non-dialysys)
​
A randomized Double-blind, Event-driven, Placebo-controlled, Multicenter Study of the Effects of Canagliflozin on Renal and Cardiovascular Outcomes in Subjects With Type 2 Diabetes Mellitus and Diabetic Nephropathy
ANDES Trial
Sponsor: Fibogen
​
Protocol: FGCL-4592-060 (non-dialysis)
​
A phase 3, Randomized, Double-Blind, Placebo Controlled Study of the Efficacy and Safety of Roxadustat (FG-4592) for the treatment of Anemia in Chronic Kidney Disease Patients not on Dialysis
SIERRAS Trial
Sponsor: Fibogen
​
Protocol: FGCL-4592-064 (dialysis)
​
A Phase 3, Open-Label, Randomized, Active-Controlled Study of the Efficacy and Safety of Roxadustat (FG4592) in the Maintenance Treatment of Anemia in End Stage Renal Disease (ESRD) Subjects on Stable Dialysis.
​
PRO2TECT Conversion Trial
​
Sponsor Akebia
​
Protocol : AKB-6548-CI-0015 (non-dialysis)
​
Title: Phase 3, randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the maintenance treatment of anemia in subjects with non-dialysis-dependent chronic kidney disease (ndd-ckd) (pro2tect - conversion)
PRO2TECT - Correction Trial
Sponsor: Akebia
​
Protocol:AKB-6548-CI-0014 (non-dialysis)
​
Phase 3, Randomized, open-label, active-controlled study evaluating the efficacy and safety of oral vadadustat for the correction of anemia in subjects with non-dialysis-dependent Chronic Kidney Disease (NDD-CKD).
ASCEND ND (non-dialysis)
Sponsor GSK
​
Protocol 200808
​
Title: A phase 3 randomized, open-label (sponsor-blind), activecontrolled, parallel-group, multi-center, event driven study in non-dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to darbepoetin alfa.
ASCEND D
Sponsor GSK
​
Protocol 200807
​
A phase 3 randomized, open-label (sponsor-blind), active controlled, parallel-group, multi-center, event driven study in dialysis subjects with anemia associated with chronic kidney disease to evaluate the safety and efficacy of daprodustat compared to recombinant human erythropoietin, following a switch from erythropoietin-stimulating agents.
COMPASS Trial
Sponsor: Keryx
​
Protocol: KRX-0502-402 (non-dialysis)
​
Title: A phase 4 study of krx-0502 (ferric citrate) dose regimens in subjects with non-dialysis dependent chronic kidney disease and iron deficiency anemia: the compass trial.